Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered mont
Healthcare and Hospitals, Health
2026-01-26 10:00 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Aleen Inc. Personal Account: Streamlined Navigation for Wellness Information
Toronto, Ontario--(Newsfile Corp. - January 26, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces the rollout of enhanced navigation features within the Personal Account, its user-facing service for managing wellness information. The improvements focus on simplifying how users browse, locate, and interact with their wellness documents. By offering more intuitive menus, faster access paths, and clearer categorization, the updates aim to make personal w
2026-01-26 8:00 AM EST | Aleen Inc.
Cheelcare Announces Medicare and Medicaid Services Reimbursement Approval for Companion Power Assist Device, Expanding U.S. Market Access
Investment Highlights: U.S. Medicare and Medicaid reimbursement eligibility achieved: The Company has received Pricing, Data Analysis, and Coding ("PDAC") verification, enabling U.S. Medicare and Medicaid reimbursement for its Companion power assist device. Companion is a best-in-class, front-mounted add-on for manual wheelchairs that provides motorized assistance, helping users enable a higher quality of life.
2026-01-26 7:30 AM EST | Cheelcare Inc.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canac
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-23 9:16 AM EST | Cardiol Therapeutics Inc.
Akanda Announces Closing of $7.0 Million Convertible Note Offering
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the closing of its previously announced transaction with institutional investors for the purchase and sale of 12 month, convertible promissory notes for an aggregate purchase price of $7.0 million, in a private placement transaction. The Company shall use the proceeds from the sale of the notes for (i) marketing purposes of up to $2.3 million, (ii) workin
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-01-23 8:00 AM EST | Akanda Corp
DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™
2026-01-22 5:00 PM EST | DiagnosTear Technologies Inc.
FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the "Agreement") dated January 20, 2026 with Aquaox LLC ("Aquaox"), a U.S. based manufacturer of environmentally
Technology, Healthcare and Hospitals, Health
2026-01-22 5:00 PM EST | FendX Technologies Inc.
Safe Supply Streaming Co Ltd. Releases Strategic Corporate Update as Commercial Traction, Government Engagement, and Platform Expansion Accelerate
Toronto, Ontario--(Newsfile Corp. - January 22, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, today provided a comprehensive corporate update as the Company enters a new phase of growth marked by commercial execution, government engagement, and strategic brand evolution. Over the past several months, Safe Supply has methodically transitioned f
2026-01-22 7:07 AM EST | Safe Supply Streaming Co Ltd.
Edison Issues Report on Noctiluca (NCL)
London, United Kingdom--(Newsfile Corp. - January 21, 2026) - Edison issues report on Noctiluca (WSE: NCL). Noctiluca is a dynamic advanced materials company specialising in OLED materials for displays and other photonics applications. It has a growing base of engagements with key players globally and is now seeing a significant acceleration driven by the breakthrough performance of its NCEIL-4 material, which has shown a 100% improvement in OLED lifetime across multiple applications. N
Banking / Financial Services, Computer Hardware, Computer Software, Health
2026-01-21 7:29 AM EST | Edison Group
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions. CBIH clarifies that this communication reflects
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-21 7:00 AM EST | Cannabis Bioscience International Holdings
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of comple
Biotechnology, Pharmaceuticals, Health
2026-01-21 3:15 AM EST | Defence Therapeutics Inc.
LevelJump Enters into Cooperation Agreement with Concerned Shareholder; Announces Board Reconstitution
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTC Pink: JMPHF) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it has entered into a cooperation agreement (the "Agreement") with Frank Teti. Under the terms of the Agreement, LevelJump has agreed to a reconstitution of its Board of Directors (the "Board") to include new independent perspectives. Effective imm
Healthcare and Hospitals, Health
2026-01-20 4:00 PM EST | LevelJump Healthcare Corp.
Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026
Winter Park, Florida--(Newsfile Corp. - January 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and personalized healthcare, today announced that it has been notified by the U.S. Securities and Exchange Commission (SEC) that its Form 10 registration statement will not be subject to further review. As a result, the Form 10 will automatically become effective 60 days after its original filing date, which is February 3, 2026. The Form 10, originally filed o
Healthcare and Hospitals, Health
2026-01-20 9:30 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 9:30 AM EST | Phio Pharmaceuticals Corp.
Functional Brands Inc. Introduces Kirkman(R) Detox Aid Bundle: a Comprehensive Approach to Heavy Metal and General Detoxification Support
Lake Oswego, Oregon--(Newsfile Corp. - January 20, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the launch of its Kirkman's Detox Aid bundle, designed to provide foundational support for detoxification-especially targeting heavy metals and environmental toxins. This innovative combination includes Detox Aid with key ingredients such as glutathione, olive leaf, selenium, and alpha-ketoglutarate (AKG), alongside
Household / Consumer / Cosmetics, Health
2026-01-20 8:00 AM EST | Functional Brands Inc.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, in
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 8:00 AM EST | BioVaxys Technology Corp.
Akanda Announces $7.0 Million Convertible Note Offering
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the execution of a securities purchase agreement with institutional investors for the purchase and sale of 12 month, convertible promissory notes for an aggregate purchase price of $7.0 million, in a private placement transaction. The closing of the transaction is expected to occur, subject to customary closing conditions, on January 21, 2026. The Com
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-01-20 8:00 AM EST | Akanda Corp